The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
Open accessAbstract
BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present a pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy. METHODS: We did a multicentre, randomised study and recruited men with localised prostate cancer between Oct 18, 2002, and Aug 12, 2006, at 11 UK centres. Patients were randomly assigned in a 1:1:1 ratio to receive conventional or hypofractionated high-dose intensity-modulated radiotherapy, and all were given with 3-6 months of neoadjuvant androgen suppression. Computer-generated random permuted blocks were used, with risk of seminal vesicle involvement and radiotherapy-treatment centre as stratification factors. The conventional schedule was 37 fractions of 2 Gy to a total of 74 Gy. The two hypofractionated schedules involved 3 Gy treatments given in either 20 fractions to a total of 60 Gy, or 19 fractions to a total of 57 Gy. The primary endpoint was proportion of patients with grade 2 or worse toxicity at 2 years on the Radiation Therapy Oncology Group (RTOG) scale. The primary analysis included all patients who had received at least one fraction of radiotherapy and completed a 2 year assessment. Treatment allocation was not masked and clinicians were not blinded. Stage 3 of this trial completed the planned recruitment in June, 2011. This study is registered, number ISRCTN97182923. FINDINGS: 153 men recruited to stages 1 and 2 were randomly assigned to receive conventional treatment of 74 Gy, 153 to receive 60 Gy, and 151 to receive 57 Gy. With 50·5 months median follow-up (IQR 43·5-61·3), six (4·3%; 95% CI 1·6-9·2) of 138 men in the 74 Gy group had bowel toxicity of grade 2 or worse on the RTOG scale at 2 years, as did five (3·6%; 1·2-8·3) of 137 men in the 60 Gy group, and two (1·4%; 0·2-5·0) of 143 men in the 57 Gy group. For bladder toxicities, three (2·2%; 0·5-6·2) of 138 men, three (2·2%; 0·5-6·3) of 137, and none (0·0%; 97·5% CI 0·0-2·6) of 143 had scores of grade 2 or worse on the RTOG scale at 2 years. INTERPRETATION: Hypofractionated high-dose radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years. FUNDING: Stage 1 was funded by the Academic Radiotherapy Unit, Cancer Research UK programme grant; stage 2 was funded by the Department of Health and Cancer Research UK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70077-9 · Cited by 1,132
Dearnaley, D. P., Sydes, M. R., Graham, J. D., Aird, E. G., Bottomley, D., Cowan, R. A., Huddart, R. A., Jose, C. C., Matthews, J. H., Millar, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70143-2 · Cited by 905
Self-citationDearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., & Horwich, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05180-0 · Cited by 739
Self-citationBrenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D., & Armour, E. P. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02664-5 · Cited by 650
Cited by
Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., Graham, J., Kirkbride, P., Logue, J., Malik, Z., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30102-4 · Cited by 1,339
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationLee, W. R., Dignam, J. J., Amin, M. B., Bruner, D. W., Low, D., Swanson, G. P., Shah, A. B., D’Souza, D. P., Michalski, J. M., Dayes, I. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0448 · Cited by 625
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C., Bangma, C., & Kataja, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 600
Self-citationDearnaley, D. P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R. A., Graham, J. D., Aird, E. G., Bottomley, D., Huddart, R. A., Jose, C. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70040-3 · Cited by 463
Self-citation
Metadata
- Authors
- Dearnaley, D., Syndikus, I., Sumo, G., Bidmead, M., Bloomfield, D., Clark, C., Gao, A., Hassan, S., Horwich, A., Huddart, R., Khoo, V., Kirkbride, P., Mayles, H., Mayles, P., Naismith, O., Parker, C., Patterson, H., Russell, M., Scrase, C., South, C., Staffurth, J., & Hall, E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 13
- Issue
- 1
- Pages
- 43-54
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2144574555
- Cited by
- 308
- References
- 34
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(11)70293-5
- The paper
- Dearnaley, D., Syndikus, I., Sumo, G., Bidmead, M., Bloomfield, D., Clark, C., Gao, A., Hassan, S., Horwich, A., Huddart, R., Khoo, V., Kirkbride, P., Mayles, H., Mayles, P., Naismith, O., Parker, C., Patterson, H., Russell, M., Scrase, C., . . . Hall, E. (2012). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(11)70293-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.